Pernix Therapeutics Holdings Inc (NASDAQ:PTX) announced that the United States Patent and Trademark Office has issued U.S. Patent Numbers 9,421,200 (‘200 patent) and 9,433,619 (‘619 patent), covering important safety information related to dosing patients with Zohydro® ER with BeadTek™. These patents, in addition to recently issued U.S. Patent Numbers 9,265,760 (‘760 patent), 9,326,982 (‘982 patent), 9,333,201 (‘201 patent) and 9,339,499 (‘499 patent), are broadly directed to methods of dosing patients with mild or moderate hepatic impairment with hydrocodone. The ‘760, ‘982, ‘201, ‘499, ‘200, and ‘619 patents expire on July 25, 2033.
“The ‘200 and ‘619 patents, solely owned by Pernix, further strengthen our intellectual property portfolio covering Zohydro ER with BeadTek,” said John Sedor, Chairman and CEO of Pernix Therapeutics. “With the addition of these patents, Zohydro ER with BeadTek currently has nine patents listed in the FDA’s Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. In addition, several other patent applications related to this product are pending.” (Original Source)
Shares of Pernix Therapeutics are up nearly 8% to $0.58 in pre-market trading. PTX has a 1-year high of $4.55 and a 1-year low of $0.39. The stock’s 50-day moving average is $0.67 and its 200-day moving average is $0.80.
On the ratings front, Brean Capital analyst Difei Yang downgraded PTX to Hold, in a report issued on August 12. According to TipRanks.com, Yang has a yearly average return of -8.6%, a 35.3% success rate, and is ranked #4000 out of 4163 analysts.
Pernix Therapeutics Holdings, Inc. engages in the research, development, and manufacture of biopharmaceutical products. It focuses on therapeutics for diseases on central nervous system, neurology, pain, and psychiatry. Its products include treatment of migraine pain and inflammation, insomnia, and depressive disorder. The firm distributes its products under the following brands: Treximet, Silenor, Zohydro ER with BeadTek, and Khedezla.